Keywords
Acetylcysteine
Cysteine
Glutamic Acid
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: This review aims to show the studies related to the acetylcysteine molecule in Alzheimer's disease, the glutamatergic hypothesis, and to show the difference of this drug in the use of medications and food supplements. Methods: The integrative review was performed in 6 detailed steps, the articles for the construction of the research were obtained from the databases Scopus; Scielo; MEDLINE, available at the Universidade Federal de Paraná-UFPR, through CAFe access. By the Boolean operators "AND" and "OR", the terms defined for data collection were obtained through the Descriptors in Health Sciences (DeCS/MeSH). Results: A total of 68 studies were found, divided among the authors; and using the inclusion and exclusion criteria, only 7 studies remained, in which were added to the search after being read in full; the studies that showed better affinity in the use of the acetylcysteine molecule associated with Alzheimer's in vivo or in vitro tests were narrated in full. Final considerations: In the research it was possible to verify that the use of N-acetylcysteine off label can be a target molecule for Alzheimer's disease, but to prove this action further studies are recommended to ensure its effectiveness.
References
ANVISA. Como a Anvisa vê o uso off label de medicamentos. Disponível em: http://antigo.anvisa.gov.br/en_US/resultado-de-busca?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-1&p_p_col_count=1&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=352702&_101_type=content&_101_grou#:~:text=Quando%20o%20medicamento%20%C3%A9%20empregado,que%20n%C3%A3o%20consta%20da%20bula.
ANDERSEN JV et al. Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration. Neuropharmacology, 2021; 196: 108719.
BENNETT ML and VIAENE AN. What are activated and reactive glia and what is their role in neurodegeneration? Neurobiol Dis. 2021 Jan; 148:105172.
CZAPSKI GA and STROSZNAJDER JB. Glutamate and GABA in microglia-neuron cross-talk in Alzheimer’s disease. International Journal of Molecular Sciences, 2021; 22(21): 11677.
CHANG CH, et al. d-glutamate and Gut Microbiota in Alzheimer's Disease. Int J Mol Sci., 2020; 21(8): 2676.
DUXIN SUN, et al. Why 90% of clinical drug development fails and how to improve it?, Acta Pharmaceutica Sinica B, 2022; 12(7): 3049-3062.
ERCOLE FF, et al. Revisão integrativa versus revisão sistemática. Revista Mineira de Enfermagem, 2014; 18(1): 9-12.
FORUM. Forum on Neuroscience and Nervous System Disorders; Board on Health Sciences Policy; Institute of Medicine. Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary. Washington (DC): National Academies Press (US); 2014 Feb 6. 2, Drug Development Challenges. Available from: https://www.ncbi.nlm.nih.gov/books/NBK195047/.
GOV. Suplementos alimentares. 16 de outubro de 2020. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/alimentos/suplementos-alimentares#:~:text=O%20que%20%C3%A9%20um%20suplemento,probi%C3%B3ticos%20em%20complemento%20%C3%A0%20alimenta%C3%A7%C3%A3o.
HSIAO YH, et al. Amelioration of social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit by N-acetylcysteine in a transgenic mouse model. Neurobiol Dis., 2012; 45(3): 1111-20.
HYND MR, et al. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int., 2004; 45(5): 583-95.
JOHNSON JW and KOTERMANSKI SE. Mechanism of action of memantine. Curr Opin Pharmacol., 2006; 6(1): 61-7.
KOIDE K, et al. The Use of 3,5,4'-Tri-O-acetylresveratrol as a Potential Pro-drug for Resveratrol Protects Mice from γ-Irradiation-Induced Death. ACS Med Chem Lett., 2011; 2(4): 270-274.
MDSYSTEMS. The Glutamatergic System in Alzheimer's Disease. (S.d) Disponível em: https://www.rndsystems.com/research-area/the-glutamatergic-system-in-alzheimer-s-disease#:~:text=The%20glutamatergic%20hypothesis%20postulates%20that,pathological%20increase%20in%20intracellular%20calcium. Acessed: Sept. 12, 2022.
MORE J, et al. N-Acetylcysteine Prevents the Spatial Memory Deficits and the Redox-Dependent RyR2 Decrease Displayed by an Alzheimer's Disease Rat Model. Front Aging Neurosci., 2018; 10: 399.
NABUCO HCG, et al. Fatores associados ao uso de suplementos alimentares entre atletas: revisão sistemática. Revista Brasileira de Medicina do Esporte, 2016; 22: 412-419.
NEELY MD, et al. Congeners of N(alpha)-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radic Biol Med., 2000; 29(10): 1028-36.
NORTH BJ and VERDIN E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol., 2004; 5(5): 224.
OOI SL, et al. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. Biomed Res Int., 2018; 2018: 2469486.
PENUGONDA S and ERCAL N. Comparative evaluation of N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) on glutamate and lead-induced toxicity in CD-1 mice. Toxicol Lett., 2011; 201(1): 1-7.
PLANALTO. Legislação no 6.360, de 23 de setembro de 1976. Disponível em: http://www.planalto.gov.br/ccivil_03/leis/l6360.htm. Acessed: Oct. 2, 2022.
PUBCHEM. National Center for Biotechnology Information. PubChem Compound Summary for CID 12035, Acetylcysteine. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/Acetylcysteine. Acessed: Oct. 2, 2022.
PUBCHEM. National Center for Biotechnology Information. "PubChem Compound Summary for CID 5862, Cysteine" PubChem. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/Cysteine. Acessed: Oct. 24, 2022.
RAGHU G, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol., 2021; 19(8): 1202-1224.
ROBINSON RA, et al. Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease. Proteomics, 2011; 11(21): 4243-56.
VAN HECKE O and LEE J. Disponível em: https://www.cebm.net/covid-19/n-acetylcysteine-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid-19/.Acess in: 12 oct. 2022.
SAUDE. Portaria nº 344, de 12 de maio de 1998. Disponível em https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html. Acessed: Oct. 2, 2022.
SCRIABINE A and RABIN DU. New developments in the therapy of pulmonary fibrosis. Adv Pharmacol., 2009; 57: 419-64.
SLATTERY J, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neuroscience & Biobehavioral Reviews, 2015; 55: 294-321.
SHAHIDI S, et al. Influence of N-acetyl cysteine on beta-amyloid-induced Alzheimer’s disease in a rat model: A behavioral and electrophysiological study. Brain research bulletin, 2017; 131: 142-149.
TARDIOLO G, et al. Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases. Molecules, 2018; 23(12): 3305.
VALLI LG. Mecanismo de ação do glutamato no sistema nervoso central e a relação com doenças neurodegenerativas. Revista Brasileira de neurologia e Psiquiatria, 2014; 18(1).
ZHANG D, et al. Opposite in vivo effects of agents that stimulate or inhibit the glutamate/cysteine exchanger system xc- on the inhibition of hippocampal LTP by Aß. Hippocampus, 2016; 26(12): 1655-1665.
FALCO AD, et al. Doença de alzheimer: hipóteses etiológicas e perspectivas de tratamento. Química Nova, 2016; 39(1).
KNOPMAN DS, et al. Alzheimer disease. Nature reviews Disease primers, 2021; 7(1): 33.